Caspase inhibitor in Phase IIb clinical trial

Published: 2009-08-20 06:57:00

Updated: 2009-08-20 06:57:00

LG Life Sciences, Ltd. (LGLS) says that its US partner Gilead Sciences is conducting a Phase IIb clinical trial in 240 patients chronically infected with the hepatitis C virus to evaluate caspase inhibitors, which was independently developed by LGLS.

In November 2007, both companies entered in...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK